Qualigen Therapeutics Stock (NASDAQ:QLGN)
Previous Close
$3.82
52W Range
$2.85 - $29.45
50D Avg
$3.59
200D Avg
$4.78
Market Cap
$2.73M
Avg Vol (3M)
$57.41K
Beta
0.03
Div Yield
-
QLGN Company Profile
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
QLGN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ZVSA | ZyVersa Therapeutics, Inc. |
| NTRB | Nutriband Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| ATNF | 180 Life Sciences Corp. |
| VRAX | Virax Biolabs Group Limited |
| IMMX | Immix Biopharma, Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| ENTX | Entera Bio Ltd. |
| REVB | Revelation Biosciences, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| SLRX | Salarius Pharmaceuticals, Inc. |